Compass Operating Cycle from 2010 to 2026
Compass Biotechnologies' Operating Cycle is decreasing with stable movements from year to year. Operating Cycle is estimated to finish at 158.08 this year. For the period between 2010 and 2026, Compass Biotechnologies, Operating Cycle quarterly trend regression had mean deviation of 15.24 and range of 98.4093. View All Fundamentals
Check out the analysis of Compass Biotechnologies Correlation against competitors. For more detail on how to invest in Compass Stock please use our How to Invest in Compass Biotechnologies guide.
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 144 | Current Value 158.08 | Quarterly Volatility 25.44242735 |
Check Compass Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Biotechnologies' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.1 K or Research Development of 109 K, as well as many indicators such as Price To Sales Ratio of 6.45, Dividend Yield of 0.0 or PTB Ratio of 5.29. Compass financial statements analysis is a perfect complement when working with Compass Biotechnologies Valuation or Volatility modules.
Compass | Operating Cycle | Build AI portfolio with Compass Stock |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out the analysis of Compass Biotechnologies Correlation against competitors. For more detail on how to invest in Compass Stock please use our How to Invest in Compass Biotechnologies guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Real Estate Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compass Biotechnologies. If investors know Compass will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compass Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Compass Biotechnologies is measured differently than its book value, which is the value of Compass that is recorded on the company's balance sheet. Investors also form their own opinion of Compass Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Compass Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compass Biotechnologies' market value can be influenced by many factors that don't directly affect Compass Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compass Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Compass Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compass Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.